– USA, CA – NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, has appointed Mark M. Sieczkarek and Dr. Massimo Radaelli to its Board of Directors.
Dr. Ron Najafi, NovaBay Chairman and Chief Executive Officer, said: “We are honored to welcome Mark and Massimo to the NovaBay Board of Directors and look forward to working with them to continue building shareholder value. Their expertise in commercialization, orphan diseases, and global product registration will prove invaluable as we move toward further commercial and clinical development of NovaBay.”
About Mark Sieczkarek
Mark M. Sieczkarek was elected Chairman of the Board of Solta Medical in June 2013 and appointed Interim President and Chief Executive Officer in August 2013. Mr. Sieczkarek has been a member of the Board of Directors since July 2006. Mark has more than 18 years of leadership experience in the medical device industry and served as President and Chief Executive Officer of Conceptus, Inc. from 2003 to 2011. Previously, Mr. Sieczkarek was Senior Vice President and President of The Americas Region, responsible for the commercial operation of all Bausch & Lomb businesses in the United States, Canada and Latin America. Mark joined Bausch & Lomb in 1995 as Vice President and Controller in the Personal Products division and also served as a Vice President in Corporate Business Development. Previously, Mark held an executive level position with KOS Pharmaceuticals, several Bristol Myers-Squibb subsidiaries and Sanofi Diagnostics Pasteur. He received a MBA degree in Finance from Canisius College in Buffalo, NY., and a B.S. degree in Accounting from the State University of New York at Buffalo.
About Massimo Radaelli, Ph.D.
Dr. Radaelli is Chairman, President & CEO of Noventia Pharma, a specialty pharmaceuticals company that he founded in 2009. Noventia Pharma operates in Southern Europe and offers a product portfolio of pharmaceuticals with a specialized business dedicated to treatments of rare and neglected diseases. Dr. Radaelli serves as Executive Chairman of Bioakos Pharma, a specialty pharmaceutical company based in Florence, Italy, focused in the areas of dermatology, gynecology and pediatrics. Dr. Radaelli is also a director of ARIAD Pharmaceuticals, Inc., a global cancer company, and a director of IDRI, a non-profit organization focused on neglected diseases. Prior to founding Noventia Pharma, Dr. Radaelli served as President and Chief Executive Officer of Dompé International SA, where he was responsible for the company’s global sales and export activities. Dr. Radaelli received a degree in pharmaceutical sciences and a Ph.D. in clinical pharmacology from the University of Milan and an Executive Master of Business degree from Bocconi University of Milan.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its Aganocide compounds, led by auriclosene. Auriclosene is a new chemical entity invented by NovaBay that has a broad spectrum of activity against bacteria, viruses and fungi. Aganocide compounds are based on the human body’s natural immune system and the molecules involved in combating infections. Bacterial resistance to Aganocides is highly unlikely, as demonstrated in published studies. Once pathogens penetrate the body’s primary defense, the next line of defense is provided by the white blood cells. NovaBay has focused on understanding these molecules generated by the white blood cells and finding ways, by chemical modification, to allow them to be developed as therapeutic products with the potential to treat a wide range of local, non-systemic infections. NovaBay believes that Aganocides will help reduce the rise of antibiotic resistance as they begin to supplant the usage of classic topical antibiotics.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
